Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
Mylan Still Mulling Revance's Botox Biosimilar
Firms Are Still In Discussions Despite Passing 30 April Deadline
May 04 2020
•
By
David Wallace
Revance is still waiting for a decision from Mylan despite passing a key date • Source: Shutterstock
More from Biosimilars
More from Products